May 22, 2020
Teva has new Ajovya nalyses and latest Copaxone Data
Teva will present new data on Ajovy and on the long-term safety and efficacy of Copaxone at at the 6th Congress of the European Academy of Neurology
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Fremanezumab
July 2, 2019
Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine
These results include reduction in monthly average migraine days; reduction in migraine related symptoms; and improvements in depression status; work productivity and activity impairment.
May 29, 2019
Teva to present new fremanezumab FOCUS Clinical Study Data for the first time at the 13th European Headache Federation Congress
Teva presents 17 posters and three oral presentations at EHF 2019 highlighting long-term and FOCUS Phase IIIb study data The…
April 24, 2019
Teva drops clinical development program for use of fremanezumab in episodic cluster headache
Teva is discontinuing the clinical developmentprogram for use of fremanezumab in cluster headaches.